Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies

Transplant-Related Hematologic Malignancy Clinical Trial

Official title:

Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01751243
• Other study ID #: ALODEPLETE
• Status: Withdrawn
• Phase: Phase 1
• Start date: January 2013
• Est. completion date: December 2018

Study information

• Verified date: September 2017
• Source: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes .

This project joins in this pioneering worldwide initiative with its own technology based on the use of proteasome inhibitors in vitro, which advantages are, over other methods described, the continuing viability of regulatory T cells and the use of a product to generate allo-depletion that, contrary to those reported by other research groups, it does not pose problems from the point of view of its use or toxicity as we employ a drug widely used clinically by intravenous administration.

Description:

The main objective of the study is to determine the safety of transplantation of hematopoietic progenitors from haploidentical donor with in vitro allo-depleted lymphocyte infusion.

Secondary objectives:

• To assess the immune reconstitution pre and post-infusion of allo-depleted lymphocytes.

• To analyze the incidence of infections (CMV and aspergillus) post-transplant.

• To analyze the impact of acute and chronic graft-versus-host disease (GVHD).

• To optimize the dose of allo-depleted lymphocytes to reconstitute an immune response against pathogens without causing GVHD.

• To assess the rate of graft and myeloid and platelet engraftment time.

• To assess the rate of relapses, event-free survival and overall survival. It is hoped to recruit 20 clinically evaluable patients for safety purpose.

The inclusion period is not more than 2 ½ years. Study duration shall not exceed three years from the inclusion of the first patient. The minimum follow-up of patients is 6 months after transplantation.

The first 5 patients (group 0) will receive haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes and then in cohorts of 3 patients, infuse +4 post-transplant day at doses of: 1x105 cluster of differentiation 3 (CD3)/kg(group 1), 3x105 CD3/kg (group 2), 5x105 CD3 / kg (group 3), 1x106 CD3/kg (group 4) and 3x106 CD3/kg (group 5).

Donor: it is performed one leukapheresis at least 30 days (4 weeks) prior to the scheduled progenitors infusion (day 0), in order to obtain effector T cells.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 50 Years

Eligibility

Inclusion Criteria:

• Adult patients aged between 16 and 50 years.

• Diagnosed as Hematological malignancy candidates to allogeneic transplant lacking of related or unrelated suitable donor (is more than one Human leukocyte antigen (HLA) mismatched over 8 antigens) and who don't have a cord with an adequate cellularity. The minimum period of search to be able to include the patient in the trial, currently considering the medium to find a suitable donor to be 2 months, it is set to 10 weeks, although in specific situations in which the responsible physician considers that the patient has a high risk of relapse, it may be proceed with inclusion before that period. These cases will be assessed individually with the trial coordinator.

Exclusion Criteria:

• General condition> Eastern Cooperative Oncology Group (ECOG) scale 2.

• Left Ventricular ejection fraction (LVEF) <39%.

• Diffusion capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) <39% of the theoretical values.

• Impaired liver function (total bilirubin higher than 2 mg / dL and / or transaminases higher than 3 times the normal maximum.

• Creatinine clearance <50 mL / minute.

• Presence of symptomatic heart, liver cirrhosis or chronic active hepatitis.

• Active tuberculosis.

• Serious diseases which prevent chemotherapy treatments.

• Associated neoplasias (active neoplasias which, according to the opinion of the investigator and the sponsor, could jeopardize patient safety).

• Presence of associated psychiatric pathology.

• HIV infection.

Related Conditions & MeSH terms

• Neoplasms
• Transplant-Related Hematologic Malignancy

Intervention

Other:
• Allo-depleted lymphocyte infusion
Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
• Haploidentical transplantation of hematopoietic progenitors
Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.

Locations

Country	Name	City	State
Spain	University Hospital Reina Sofia	Cordoba
Spain	University Hospital Carlos Haya	Malaga
Spain	University Hospital de Salamanca	Salamanca
Spain	University Hospital Virgen del Rocío	Sevilla

Sponsors (2)

Lead Sponsor	Collaborator
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud	Iniciativa Andaluza en Terapias Avanzadas

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events and serious adverse events after allo-depleted lymphocyte infusion in vitro.		6 months
Secondary	Incidence of acute and chronic GVHD		6 months

External Links

•   Andalusian Initiative for Advanced Therapies
•   Andalusian Molecular Biology and Regenerative Medicine Centre